Giant cell arteritis and cardiovascular disease in older adults

J G Ray, M M Mamdani, W H Geerts

Objective: To explore the association between giant cell arteritis (GCA) and subsequent cardiovascular disease in older adults.

Design: Population based retrospective cohort study.

Setting: The entire province of Ontario, Canada.

Participants: Patients aged 66 years and older, with newly diagnosed GCA (n = 1141), osteoarthritis (n = 172 953), or neither condition (n = 200 000). Patients with neither were randomly selected from the general population and formed the control group.

Main outcome measures: The primary composite outcome was based on a subsequent diagnosis or surgical treatment for coronary artery disease, stroke, peripheral arterial disease, or aneurysm or dissection of the aorta.

Results: The composite end point was more common in seniors with GCA (12.1/1000 person-years) than in patients with osteoarthritis (7.3/1000 person-years) or neither condition (5.3/1000 person-years). The adjusted hazard ratio for cardiovascular disease was 1.6 (95% confidence interval (CI) 1.1 to 2.2) in patients with GCA versus patients with osteoarthritis, and 2.1 (95% CI 1.5 to 3.0) in patients with GCA versus unaffected controls.

Conclusions: Older adults with GCA appear to be at increased risk for developing cardiovascular disease. Whether an aggressive approach to cardiovascular disease modification is particularly beneficial in these patients remains to be determined.
adjusted for newly prescribed warfarin or newly diagnosed cancer if either occurred after study entry, as outlined below.

The primary cardiovascular disease outcome was a composite diagnosis or surgical treatment of any one of the following: coronary artery disease, stroke, peripheral arterial disease, or aneurysm or dissection of the aorta. Coronary artery disease was defined according to the International classification of diseases, 9th revision, (ICD-9) codes related to angina, myocardial infarction, or coronary artery revascularisation (see Appendix). Cerebrovascular disease was defined by all ICD-9 codes related to stroke or carotid endarterectomy. Peripheral arterial disease was based on a coding for peripheral vascular disease or peripheral artery revascularisation. Aneurysm or dissection the aorta required a coded diagnosis of either condition in the non-ruptured, ruptured, or surgically repaired state (see Appendix). It was a requisite that a diagnosis of GCA or osteoarthritis precede the diagnosis of cardiovascular disease.

The period of observation was from 1 January 1995 to 31 March 2002. The databases were sampled from 1 January 1992 to 31 March 2002 to account for the presence of antecedent inclusion and exclusion criteria. A participant in one exposure group was censored either if he or she had a disease diagnosis from another group or if he or she experienced a cardiovascular disease outcome event, died during the study period, or reached the end of follow up to 31 March 2002.

Hospitalisation records were obtained from the Canadian Institute for Health Information Discharge abstract database, which was used to categorise patients as having GCA, osteoarthritis, or neither, as well as all subsequent events and co-morbid illnesses, both diagnostic and procedural. Discharge abstract database records contain the unique health care number, age and sex of the patient, date of admission, and up to 16 diagnoses coded according to the ICD-9 system (see Appendix). The OHIP database was also used to identify baseline and subsequent disease events. This database contains records of all physician billing information for outpatient and inpatient services, including a service date and diagnosis. Participant age and sex were retrieved from the Registered persons database, which contains demographic information and health care numbers for all people eligible for OHIP. Finally, the Ontario drug benefits database was used to identify the medications each elderly participant was prescribed at any point during the period of observation, irrespective of the number of prescriptions or days supplied. This database is maintained by the Ontario Ministry of Health and Long-Term Care and records encrypted patient identifiers, prescription dates, and drug information for all residents of Ontario aged 65 years or greater.

### Statistical analysis

Time to event was analysed by Cox’s proportional hazards regression model. Risk was expressed as an unadjusted and adjusted hazard ratio (HR) and 95% confidence interval (CI). Age, sex, hospitalisation within one year before study entry, newly diagnosed cancer, currently prescribed medications for the treatment of hyperglycaemia or hypertension, and current prescription of a lipid lowering agent, aspirin, warfarin, oestrogen, non-steroidal anti-inflammatory drug (including cyclo-oxygenase 2 (COX-2) inhibitors), or prednisone, methylprednisone, azathioprine or methotrexate were the adjusted factors. All participants were identified as being exposed to a potential confounder if the confounding event occurred at any time between 100 days before study entry and the end of follow up.

All p values were two sided at a significance level of 0.05. All statistical analyses were performed with SAS for UNIX version 8.2. The three health care databases were linked anonymously by encrypted individual health card numbers. The control group of 200 000 unaffected patients were selected to ensure that at least 10% of the existing population of seniors would form that group. This study was approved by the ethics review board of Sunnybrook and Women’s College Health Sciences Centre, Toronto.

### RESULTS

A total of 1141 patients with GCA, 172 953 patients with osteoarthritis, and 200 000 unaffected controls were studied, corresponding to 3061, 434 025, and 640 637 person-years of follow up (table 1). Of the patients with a diagnosis of GCA, 283 (25%) had a submitted physician OHIP billing code for temporal artery biopsy within 30 days of the index date of diagnosis. The general characteristics and respective drug prescription rates were similar among patients with GCA, osteoarthritis, and neither, with the exception of prescribed anti-hyperglycaemic drugs (16%, 12%, and 11%), lipid lowering drugs (23%, 24%, and 21%), aspirin (28%, 22%, and 21%), non-steroidal anti-inflammatory drugs (34%, 49%, and 37%), and systemic corticosteroids (47%, 12%, and 14%, respectively) (table 1).

For the primary composite outcome, there were 37 (12.1/1000 person-years) cardiovascular events in the GCA group, 3172 (7.3/1000 person-years) events in the osteoarthritis

---

**Table 1** Baseline characteristics of the study cohort

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Disease exposure group</th>
<th>Unaffected controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GCA (n = 1141)</td>
<td>Osteoarthritis (n = 172 953)</td>
</tr>
<tr>
<td>Duration of follow up (person-years)</td>
<td>3 061</td>
<td>434 025</td>
</tr>
<tr>
<td>Age (years)</td>
<td>75.2 (6.5)</td>
<td>74.9 (6.8)</td>
</tr>
<tr>
<td>Men</td>
<td>463 (41%)</td>
<td>67 429 (39%)</td>
</tr>
<tr>
<td>Cancer</td>
<td>33 (3%)</td>
<td>3180 (2%)</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihyperglycaemic drug</td>
<td>187 (16%)</td>
<td>21 046 (12%)</td>
</tr>
<tr>
<td>Oestrogen</td>
<td>98 (9%)</td>
<td>15 353 (9%)</td>
</tr>
<tr>
<td>Lipid lowering drug</td>
<td>288 (25%)</td>
<td>41 764 (24%)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>322 (28%)</td>
<td>38 318 (22%)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>76 (7%)</td>
<td>7 118 (4%)</td>
</tr>
<tr>
<td>NSAID</td>
<td>386 (34%)</td>
<td>84 872 (49%)</td>
</tr>
<tr>
<td>Prednisone or methylprednisone</td>
<td>540 (47%)</td>
<td>20 163 (12%)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12 (1%)</td>
<td>125 (&lt;1%)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>4 (&lt;1%)</td>
<td>254 (&lt;1%)</td>
</tr>
</tbody>
</table>

Data are mean (SD) or number (%). GCA, giant cell arteritis; NSAID, non-steroidal anti-inflammatory drug.
group, and 3401 (5.3/1000 person-years) events among the unaffected controls (table 2, fig 1). There was a heightened associated risk for cardiovascular disease among patients with diagnosed GCA compared with patients with osteoarthritis (crude HR 1.6, 95% CI 1.2 to 2.2) or neither disease (crude HR 2.4, 95% CI 1.7 to 3.3). After adjustment for certain potential confounders, the HR remained significant when patients with GCA were compared with the osteoarthritis (1.6, 95% CI 1.1 to 2.2) or unaffected (2.1, 95% CI 1.5 to 3.0) controls (table 2). This risk difference became more apparent with time (fig 1).

Compared with unaffected controls, there was a significant association between GCA and the crude risk of coronary artery disease (HR 2.1, 95% CI 1.4 to 3.2), stroke (HR 2.2, 95% CI 1.0 to 4.9), peripheral arterial disease (HR 5.2, 95% CI 1.7 to 16.5), and aortic aneurysm or dissection (HR 3.5, 95% CI 1.1 to 11.0) (table 2). After adjustment for potential confounders, all patient outcomes remained significant, with the exception of a non-significant trend for stroke (adjusted HR 2.1, 95% CI 0.9 to 4.6) (table 2).

In a post hoc analysis, we limited the GCA cohort to patients who were prescribed corticosteroids. The incidence of the composite cardiovascular end point was higher among these 540 patients (9.4/1000 person-years) than among patients with a diagnosis of osteoarthritis (7.3/1000 person-years) or neither condition (5.3/1000 person-years). In a comparison between patients with GCA prescribed steroids and unaffected controls, the crude HR was 1.9 (95% CI 1.1 to 3.3). A non-significant trend remained after adjustment for all covariates except prescribed corticosteroids (adjusted HR 1.6, 95% CI 0.9 to 2.8).

**DISCUSSION**

In a large retrospective population based cohort study, we observed roughly a doubling of the associated risk of diagnosed cardiovascular disease among patients with GCA compared with unaffected controls and a 60% increased risk with GCA relative to patients with osteoarthritis.

**Study limitations**

The diagnosis of GCA depends on clinical symptoms and signs and is enhanced by non-specific (for example, erythrocyte sedimentation rate) and specific (for example, arterial biopsy) laboratory findings. Only 25% of patients with a diagnosis of GCA had a procedural billing code submitted by a physician for temporal artery biopsy within 30 days of the diagnosis of GCA. This may be explained partly by delayed billing practices, the low reliability of procedural codes, and the fact that many cases of GCA are not biopsy proven. However, since some patients with a diagnosis of GCA may not have had biopsy proven disease, disease exposure misclassification was a possibility—a limitation of using large administrative databases for research purposes.

Non-differential misclassification (that is, an equal chance of misclassification of the exposure between diseased and non-diseased participants) would likely have led to an underestimate of the true relation between GCA and cardiovascular disease. Although the diagnostic coding for cardiovascular disease and related co-morbidity events appears to be accurate, it is possible that vascular disease was more commonly suspected or diagnosed in patients with GCA, partly because they may receive more thorough clinical care and follow up. Finally, although 1141 patients with GCA were studied, only six had a diagnosis of stroke and three of peripheral arterial disease or aortic disease, probably generating underpowered risk estimates. We were unable to identify whether these events were caused by atherothrombosis or aortitis.

**Other published evidence**

A higher associated risk between GCA or polymyalgia rheumatica and all cause mortality has been observed in previous small studies but not consistently so. Even less is known about the relation between GCA and cardiovascular disease. In one report of 96 patients with GCA, the incidence of thoracic and abdominal aortic aneurysm was higher than expected, at 1.0 and 0.6/1000 person-years, respectively. In a second study, 171 patients with GCA or polymyalgia rheumatica were followed up for up to two decades. An increased risk of cardiovascular death was observed among both women (standardised mortality ratio 1.5, 95% CI 1.2 to 1.9) and men (standardised mortality ratio 1.9, 95% CI 1.6 to 2.3).
were at increased risk of myocardial infarction (adjusted risk ratio 1.6, 95% CI 1.1 to 2.2), mainly due to ischaemic heart disease.29

Mechanisms of disease

There are several plausible mechanisms to explain the observed association between GCA and cardiovascular disease. The focal vasculitis of GCA may produce acute arterial occlusion and secondary stroke or myocardial infarction or it can progress to luminal ectasia, with dissection or aneurysm of the aorta.30 GCA may also induce reactive thrombocytosis31 and hyperfibrinoginaemia,32 predisposing to atherothrombosis.33 At a third level of reasoning, GCA and cardiovascular disease may share certain risk factors, such as heavy cigarette smoking.34 Similarly, C pneumoniae infection35–37 and high cardiolipin antibody titres38–40 are each risk factors for both GCA and cardiovascular disease. In one study, C pneumoniae was isolated in eight of nine temporal artery biopsies of patients with GCA, predominantly from within the granulomatous infiltrates of the vascular adventitia, compared with none of the nine controls whose biopsies were negative for GCA.41 In a prospective case–control study, cardiolipin antibodies were present in 21% of all patients with GCA but in only 3% of controls.42 The prevalence of antibodies among patients whose temporal artery biopsy was GCA positive (31%) was nearly twice that of patients with suspected cases whose biopsy was negative (17%).42

Perhaps the most compelling contemporary explanation linking GCA with cardiovascular disease is the presence of chronic inflammation. A robust body of evidence supports a link GCA with chronic inflammation and cardiovascular disease risk.14 15 Inflammatory cytokines, including interleukin 6, are directly liberated from GCA granulomata.17 These cytokines potently stimulate production of fibrinogen and certain acute phase reactants, including C reactive protein, a strong risk marker of cardiovascular disease.18 19 Patients with inflammatory rheumatoid arthritis also appear to be at increased risk of cardiovascular disease.19 For example, a recent large comparative study of adults with rheumatoid arthritis also appear to be at increased risk of cardiovascular disease.19 20

APPENDIX

<table>
<thead>
<tr>
<th>Disease</th>
<th>Diagnosis or procedure</th>
<th>ICD-9 code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giant cell arteritis</td>
<td>Giant cell arteritis</td>
<td>446.5</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Polymyalgia rheumatica</td>
<td>725</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Osteoarthritis</td>
<td>715</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Angina</td>
<td>413, 414.0</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Myocardial infarction</td>
<td>410, 411</td>
</tr>
<tr>
<td>Carotid endarterectomy</td>
<td>Carotid angioplasty or coronary stent insertion or coronary artery bypass grafting</td>
<td>36.0, 36.1, 36.2, 36.3</td>
</tr>
<tr>
<td>Stroke</td>
<td>Stroke</td>
<td>433.43, 437.0, 437.1</td>
</tr>
<tr>
<td>Stroke</td>
<td>Cerebrovascular accident and atherosclerosis</td>
<td>437.0, 437.1</td>
</tr>
<tr>
<td>Stroke</td>
<td>Carotid endarterectomy</td>
<td>38.11, 38.12</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>Peripheral vascular bypass or peripheral artery endarterectomy</td>
<td>38.18, 38.48, 39.24, 39.25, 39.26, 39.29, 39.5</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Atherosclerosis of aorta</td>
<td>440.0</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Atherosclerosis of peripheral arteries</td>
<td>440.2</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Arterial embolism and thrombosis</td>
<td>444</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Aortic aneurysm or dissection</td>
<td>444</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Peripheral vascular disease, unspecified</td>
<td>443.9</td>
</tr>
<tr>
<td>Aortic aneurysm or dissection</td>
<td>Repair of aortic aneurysm</td>
<td>38.44, 38.45, 39.54</td>
</tr>
</tbody>
</table>

* Considered in the exclusion of patients within the 36 month period before study entry but not used to define the cohort with giant cell arteritis.

The risk of the cardiovascular disease composite was significantly higher among patients with GCA than among patients with osteoarthritis but not for the individual subtypes of cardiovascular disease (table 2). This phenomenon may be explained both by a diminution in statistical power created by subgroup multivariate analysis and by the greater presence of cardiovascular risk factors among patients with osteoarthritis than among a non-arthritic population.15 16 For example, in the US third national health and nutrition examination survey of patients with osteoarthritis, the prevalence of hypertension was 40%, hypercholesterolaemia 32%, and diabetes mellitus 11%, all of which are more commonly seen in overweight adults.18

Because of the low coding accuracy within administrative databases,16 we did not establish a control group of seniors with rheumatoid arthritis. Comparing patients with GCA versus patients with rheumatoid arthritis and estimating their relative risk of cardiovascular disease may clarify the degree to which chronic systemic inflammation is a mediator of vascular injury or arteriosclerosis. We saw only a minor decline in the estimated risk of cardiovascular disease among patients with GCA after adjusting for prescribed corticosteroids, azathioprine, or methotrexate in the multivariate model. At the same time, we could not precisely exclude some modifying effect of these agents, since cumulative drug doses were not documented.

Clinical ramifications

How do these data affect clinical management of GCA after the recommended use of immunosuppressive agents in the acute phase of the disease?17 18 Since preliminary data suggest that patients with GCA may be at increased risk of cardiovascular disease, they may particularly benefit from risk factor modification, including control of hypertension, hyperglycaemia, dyslipidaemia, and tobacco use. Low dose aspirin may attenuate the inflammatory response seen with...
GCA, as well as the long term risk of cardiovascular disease. Similarly, statin drug use may conceivably contribute to an overall reduction in cardiovascular risk among patients with GCA and increased C reactive protein. These assumptions would be best tested in an observational study or a randomised clinical trial.

Research ramifications

Through multicentre collaboration, future researchers should also attempt to accurately classify and compare cardiovascular disease and related mortality among patients with and without GCA. Our post hoc subgroup analysis suggested that patients with GCA who are prescribed corticosteroids may experience a slightly lower rate of cardiovascular disease than patients not prescribed steroids. It would be worthwhile knowing whether GCA disease activity—reflected or according to ongoing steroid requirements—is correlated with cardiovascular disease. Examining sensitive and specific indicators of inflammation, alongside measured cardiolipin antibodies and certain markers of infection, may enhance our understanding of the pathophysiology linking GCA to cardiovascular disease. Finally, better documentation of the timing between the initial manifestation of GCA and that of cardiovascular disease, with a longer duration of follow up, may help clarify whether arterial occlusion is directly related to the arteritis, to secondary thrombosis, or to a more gradual progression to atherosclerosis.

ACKNOWLEDGMENTS

Thanks to Dr Donald A Redelmeier for his constructive comments in the design and presentation of this study.

Authors’ affiliations

J G Ray, Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
M M Mambani, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
W H Geerts, Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada

*Also the Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

Potential conflict of interest: none.

REFERENCES